We further validated the PTEN-SSL activities of the AMPK pathway members STK11 and NUAK1. We confirmed by small-molecule inhibition by HTH-01-015 that NUAK1 constitutes a novel PTEN-SSL vulnerability across a broad-spectrum of breast cancer cell lines. This evidence concerns the gene PTEN and breast carcinoma.